INDICTED: Criminal charges filed against hedge fund in bapineuzumab case
This article was originally published in Scrip
Executive Summary
US prosecutors on 25 July brought criminal charges against Stamford, Connecticut-based SAC Capital Advisors – a hedge fund that, until recently, managed portfolios of over $15bn – in a case involving insider trading surrounding clinical trial results of a now defunct Alzheimer's drug, bapineuzumab.